Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM | Zendy

Anders Boyd | Zendy; Patrick Miailhes | Zendy; Julie Chas | Zendy; MarcAntoine Valantin | Zendy; Yazdan Yazdanpanah | Zendy; Éric Rosenthal | Zendy; Stéphane Chevaliez | Zendy; Lionel Piroth | Zendy; Hayette Rougier | Zendy; Gilles Peytavin | Zendy; Gilles Pialoux | Zendy; PierreMarie Girard | Zendy; Karine Lacombe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM

Author(s) -

Anders Boyd,

Patrick Miailhes,

Julie Chas,

MarcAntoine Valantin,

Yazdan Yazdanpanah,

Éric Rosenthal,

Stéphane Chevaliez,

Lionel Piroth,

Hayette Rougier,

Gilles Peytavin,

Gilles Pialoux,

PierreMarie Girard,

Karine Lacombe

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa091

Subject(s) - medicine , adverse effect , population , clinical endpoint , viral load , coinfection , men who have sex with men , clinical trial , virology , human immunodeficiency virus (hiv) , environmental health , syphilis

In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research